Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial Setting

Related

• 

  Intravitreal Gene Therapy for Diabetic Macular Edema With ADVM-022: First-Time Data Presentation of Prospective, Randomized Phase 2 INFINITY Trial

  Charles C Wykoff, MD, PhD, FASRS

  Updates from the Field

  2021

• 

  Pediatric Cases That All Retina Surgeons Will Encounter

  Audina M. Berrocal, MD FASRS

  Yoshihiro Yonekawa, MD, FASRS

  Philip J. Ferrone, MD, FASRS

  Caroline Baumal, MD

  Lejla Vajzovic, MD, FASRS

  Emmanuel Chang, MD PhD FACS

  Webinars and Journal Clubs

  2022

• 

  Interim 12-Month Results from PALADIN in Diabetic Macular Patients Receiving ILUVIEN: Analysis of the Prior Dexamethasone Cohort

  Daniel F. Kiernan, MD, FACS

  On Demand Cases, Courses, and Papers

  2019